Filing Flows

Filing Flows › Companies › Accustem Sciences › Cash flow

Accustem Sciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$249K in Q2 2026 · −$1.2M over twelve months

Operating cash flow−$249K
Free cash flow−$249K

Analysis

In Q2 2026, Accustem Sciences generated −$249K of operating cash flow. That is $270K less than in Q2 2025 ($22K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$1.2M; the largest uses were operating cash flow ($1.2M), net borrowing (+) / repaid (−) ($94K); besides operations, cash came from other financing ($1.3M); the cash balance fell by $18K.

Operating cash flow was −$249K against net income of −$253K. The largest differences: payables −$122K, prepaid and other assets +$32K, stock-based pay +$7K.

Free cash flow

Accustem Sciences: free cash flow by quarterAccustem Sciences: free cash flow by quarter−$218KQ3 2024$414Q4 2024−$290KQ1 2025$22KQ2 2025−$604KQ3 2025$22KQ4 2025−$374KQ1 2026−$249KQ2 2026
Operating cash flow less capital spending.
Accustem Sciences: operating cash flow against capital spendingAccustem Sciences: operating cash flow against capital spendingOperating cash flowCapital spending−$218K$0Q3 2024$414$0Q4 2024−$290K$0Q1 2025$22K$0Q2 2025−$604K$0Q3 2025$22K$0Q4 2025−$374K$0Q1 2026−$249K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$249K, Capital spending $0.

Capital allocation, year by year

Accustem Sciences: where the cash came from (up) and went (down), by fiscal yearAccustem Sciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2022: Operating cash flow −$1.8MFY2022: Net borrowing −$338KFY2022: Shares issued $2.7MFY2022: Capital spending −$11K$2.7MFY2022FY2023: Operating cash flow −$1.6MFY2023FY2024: Operating cash flow −$664KFY2024: Net borrowing −$133KFY2024FY2025: Operating cash flow −$850KFY2025: Net borrowing −$98KFY2025
Over these 4 years operating cash flow totalled −$4.9M; the largest uses were operating cash flow ($4.9M) and net borrowing ($569K). Cash-flow statements as filed.

Where the cash came from and went

Accustem Sciences: sources (+) and uses (−) of cash, Q2 2026Accustem Sciences: sources (+) and uses (−) of cash, Q2 2026Other financing$275KOperating cash flow−$249KNet borrowing (+) / repaid (−)−$25KCash drawn (+) / kept (−)−$1K
Accustem Sciences: sources (+) and uses (−) of cash, TTM to Q2 2026Accustem Sciences: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$1.3MOperating cash flow−$1.2MNet borrowing (+) / repaid (−)−$94KCash drawn (+) / kept (−)$18K

From profit to cash

Accustem Sciences: net income to operating cash flow, Q2 2026Accustem Sciences: net income to operating cash flow, Q2 2026Net income−$253KStock-based pay$7KPayables−$122KPrepaid and other assets$32KOperating cash flow−$249K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026−$249K−$25K−$1K−$249K
Q1 2026−$374K−$23K$2K−$374K
Q4 2025$22K−$23K$463$22K
Q3 2025−$604K−$23K$17K−$604K
Q2 2025$22K−$27K$5K$22K
Q1 2025−$290K−$25K−$31K−$290K
Q4 2024$414−$32K$32K$414
Q3 2024−$218K−$24K$9K−$218K

Accustem Sciences: income statement and cash flow

Accustem Sciences, Q2 2026: revenue $98K, operating margin -256.7%. The chart follows the revenue to costs, profit and cash.

Accustem Sciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.